高压氧治疗对慢性脑缺血大鼠认知功能的影响及其作用机制

目的 探讨高压氧（hyperbaric oxygen，HBO）治疗对慢性脑缺血（chronic cerebral ischemia，CCI）大鼠 学习记忆能力的影响及其作用机制。 方法 选取240只雄性SD大鼠随机分为假手术组、CCI组和HBO组，每组80只。采用双侧颈总动脉阻 断法建立CCI模型，HBO组建模12 h后开始进行HBO治疗28 d，压力0.2 MPa，每日1次，每次60 mi n。采用 Morri s水迷宫实验评估7、14、21、28 d大鼠的学习记忆能力，每个时间点20只，检测前均进行3 d训练， 记录各组大鼠的逃避潜伏时间、穿越平台次数。28 d后处死大鼠取海马组织进行HE染色评估神经元 损伤病理变化，RT-PCR法检测Nogo-A mRNA，Western blot法检测Nogo-A蛋白的表达水平。 结果 ①与假手术组比较，CCI 组7、14、21、28 d逃避潜伏时间均延长（均P＜0.05），28 d跨越平台次 数减少（P＜0.05）；与CCI 组比较，HBO组7、14、21、28 d逃避潜伏时间均缩短（均P＜0.05），28 d跨越 平台次数增加（P＜0.05）。②HE染色显示HBO组神经元损伤程度较CCI组减轻；③CCI组Nogo-A mRNA 和Nogo-A蛋白表达水平均较假手术组升高（均P＜0.05），HBO组表达水平均较CCI组下降（P＜0.05）。 结论 HBO治疗可改善慢性脑缺血大鼠认知功能，其机制可能与下调海马组织中Nogo-A的表达水平 有关。     

急诊住院医师的教学查房模式

教学查房是床旁教学的一种重要手段,对住院医师进行教学查房能够有效提高住院医师的岗位胜任力和职业能力,培养急诊住院医师的急诊临床思维。近年来由于国家住院医师规范化培训改革在不断深入,对急诊住院医师的教学查房引起了人们的高度关注,然后在实际的急诊住院医师的教学查房中却还存在着诸多问题,教学查房与日常的临床查房概念混淆、教学查房准备不充分、教学查房目的不明确以及教学查房的互动性不强都严重影响了教学查房的质量。因此需要积极探究急诊住院医师的教学查房的有效模式,从而不断提升住院医师的临床实践能力。     

亮氨酸氨基肽酶在妊娠妇女血清中的水平变化及其意义

目的:探讨血清亮氨酸氨基肽酶(LAP)在妊娠妇女不同时期血清中的变化规律及其临床意义。方法:选取2011年1月~2013年12月在该院产检的正常妊娠妇女180例,根据孕周分为早期组、中期组和晚期组,每组各60例,另选取60例健康未孕妇女为未孕组;同时选取该院收治的妊娠期高血压疾病妇女33例为妊娠期高血压疾病组、早产孕妇22例为早产组,采用速率法分别检测各组孕妇血清LAP水平并进行比较。结果:未孕组、早期组、中期组、晚期组妇女的血清LAP、血清肝胆酸(CG)、碱性磷酸酶(ALP)、α-L-岩藻糖苷酶(AFU)水平比较,差异有统计学意义(P均<0.05)。妊娠期高血压疾病组的CG、ALP、AFU、LAP水平显著高于早期组、中期组和晚期组(P均<0.05);早产组的CG、ALP、AFU、LAP水平显著高于早期组、中期组(P均<0.05),仅CG水平高于晚期组(P<0.05)。结论:随着妊娠周期的增加,妊娠妇女的血清LAP水平逐步升高,在合并妊娠期高血压疾病时LAP升高更加显著,结合CG、ALP、AFU水平的变化能够对妊娠期高血压疾病的发病情况进行动态监测。     

Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup

Diffuse large B-cell lymphoma (DLBCL) is a clinically aggressive and heterogenous disease. Although most patients can be cured by immunochemotherapy, 30% to 40% patient will ultimately develop relapsed or refractory disease. Here, we investigated the molecular landscapes of patients with diverse responses to R-CHOP. We performed capture-based targeted sequencing on baseline samples of 105 DLBCL patients using a panel consisting of 112 lymphoma-related genes. Subsequently, 81 treatment-naïve patients with measurable disease and followed for over 1 year were included for survival analysis. Collectively, the most commonly seen mutations included IGH fusion (69%), PIM1(33%), MYD88 (29%), BCL2 (29%), TP53 (29%), CD79B (25%) and KMT2D (24%). Patients with TP53 mutations were more likely to have primary refractory disease (87.0% vs 50.0%, P = .009). For those with TP53 disruptive mutations, 91.7% patients were in the primary refractory group. Interestingly, BCL-2 somatic hypermutation was only seen in patients without primary refractory disease (P = .014). In multivariate analysis, BCL-2 amplification (hazard ratio [HR] = 2.94, P = .022), B2M mutation (HR = 2.99, P = .017) and TP53 mutation (HR = 3.19, P < .001) were independently associated with shorter time to progression (TTP). Furthermore, TP53 mutations was correlated with worse overall survival (P = .049). Next, we investigated mutation landscape in patients with wild-type (WT) TP53 (n = 58) and found that patients harboring MYD88 L265P had significantly inferior TTP than those with WT or non-265P (P = .046). Our study reveals the mutation spectrum of treatment-naive Chinese DLBCL patients. It also confirms the clinical significance of TP53 mutations and indicates the prognostic value of MYD88 L265P in TP53 WT patients.     

Aloe‐emodin: A review of its pharmacology,toxicity, and pharmacokinetics

Aloe‐emodin is a naturally anthraquinone derivative and an active ingredient of Chinese herbs, such as Cassia occidentalis, Rheum palmatum L., Aloe vera, and Polygonum multiflorum Thunb. Emerging evidence suggests that aloe‐emodin exhibits many pharmacological effects, including anticancer, antivirus, anti‐inflammatory, antibacterial, antiparasitic, neuroprotective, and hepatoprotective activities. These pharmacological properties lay the foundation for the treatment of various diseases, including influenza virus, inflammation, sepsis, Alzheimer's disease, glaucoma, malaria, liver fibrosis, psoriasis, Type 2 diabetes, growth disorders, and several types of cancers. However, an increasing number of published studies have reported adverse effects of aloe‐emodin. The primary toxicity among these reports is hepatotoxicity and nephrotoxicity, which are of wide concern worldwide. Pharmacokinetic studies have demonstrated that aloe‐emodin has a poor intestinal absorption, short elimination half‐life, and low bioavailability. This review aims to provide a comprehensive summary of the pharmacology, toxicity, and pharmacokinetics of aloe‐emodin reported to date with an emphasis on its biological properties and mechanisms of action.